{"id":8384,"date":"2020-07-21T15:53:39","date_gmt":"2020-07-21T22:53:39","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8384"},"modified":"2021-04-02T15:54:24","modified_gmt":"2021-04-02T22:54:24","slug":"experience-with-tocilizumab-in-severe-covid-19-pneumonia-after-80-days-of-follow-up-a-retrospective-cohort-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/21\/experience-with-tocilizumab-in-severe-covid-19-pneumonia-after-80-days-of-follow-up-a-retrospective-cohort-study\/","title":{"rendered":"Experience with Tocilizumab in Severe COVID-19 Pneumonia after 80 Days of Follow-up: A Retrospective Cohort Study"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"43\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Among 236 patients with severe COVID-19 pneumoni<\/span><span data-contrast=\"auto\">a treated with tocilizumab over a median follow-up of 83 days<\/span><span data-contrast=\"auto\">,<\/span><span data-contrast=\"auto\">\u00a05<\/span><span data-contrast=\"auto\">5<\/span><span data-contrast=\"auto\">% required ICU admission, 49% required invasive mechanical venti<\/span><span data-contrast=\"auto\">l<\/span><span data-contrast=\"auto\">ation, and 1<\/span><span data-contrast=\"auto\">3<\/span><span data-contrast=\"auto\">% died<\/span><span data-contrast=\"auto\">.<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">The<\/span><span data-contrast=\"auto\">\u00a0investigators\u00a0<\/span><span data-contrast=\"auto\">evaluated\u00a0<\/span><span data-contrast=\"auto\">response to tocilizumab using multiple<\/span><span data-contrast=\"auto\">\u00a0methods<\/span><span data-contrast=\"auto\">\u00a0and found that the response defined<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">by<\/span><span data-contrast=\"auto\">\u00a0stable or decreasing scores on the\u00a0<\/span><span data-contrast=\"auto\">Lower Brescia COVID Respiratory Severity Scale\u00a0<\/span><span data-contrast=\"auto\">was associated with lower odds of mortality (OR=<\/span><span data-contrast=\"auto\">0.1<\/span><span data-contrast=\"auto\">4, 95% CI 0.03\u00a0<\/span><span data-contrast=\"auto\">\u2013<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">0.74), while<\/span><span data-contrast=\"auto\">\u00a0response defined by other methods was not associated with mortality<\/span><span data-contrast=\"auto\">.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Moreno-P\u00e9rez et al. (July 16, 2020). Experience with Tocilizumab in Severe COVID-19 Pneumonia after 80 Days of Follow-up: A Retrospective Cohort Study. Journal of Autoimmunity.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.jaut.2020.102523\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/j.jaut.2020.102523<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among 236 patients with severe COVID-19 pneumonia treated with tocilizumab over a median follow-up of 83 days,\u00a055% required ICU admission, 49% required invasive mechanical ventilation, and 13% died.\u00a0The\u00a0investigators\u00a0evaluated\u00a0response to tocilizumab using multiple\u00a0methods\u00a0and found that the response defined\u00a0by\u00a0stable or decreasing scores on the\u00a0Lower Brescia COVID Respiratory Severity Scale\u00a0was associated with lower odds of mortality (OR=0.14, 95%&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/21\/experience-with-tocilizumab-in-severe-covid-19-pneumonia-after-80-days-of-follow-up-a-retrospective-cohort-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-8384","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8384"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8384\/revisions"}],"predecessor-version":[{"id":8385,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8384\/revisions\/8385"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8384"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}